Australia is entering an important new phase for genomics and precision medicine, with growing momentum to move from research and individual programs towards clinical implementation and mainstream healthcare. InGeNA is delighted to host Dame Professor Sue Hill, Chief...
Professor Joanne Ngeow shared Singapore’s experience in building population genomics evidence and translating it into cancer prevention, clinical services and national reimbursement. Singapore’s National Precision Medicine Program began by sequencing 10,000 people,...
InGeNA welcomes our new associate member Bespoke Genetic Medicines Inc InGeNA is delighted to welcome our new Associate Member: Bespoke Genetic Medicines Inc. Where Traditional pharmaceutical companies develop one drug for millions of patients, at Bespoke Genetic...
InGeNA welcomes our new partner the Griffith University Institute for Biomedicine and Glycomics InGeNA is delighted to welcome Griffith University’s Institute for Biomedicine and Glycomics as our newest partner. IBG is a multidisciplinary biomedical research institute...
A Nature news feature has profiled a new wave of companies developing a different kind of gene therapy. Rather than cutting DNA, these therapies change the chemical markers that sit on it and switch genes on or off. The approach is called epigenetic editing. The...
A new study in the New England Journal of Medicine reports promising results from a CRISPR gene-editing therapy in children aged 5 to 11. The children had severe sickle cell disease or transfusion-dependent beta thalassaemia, both inherited blood disorders. HCA...
